177Lu-DOTA-IBA Therapy in Prostate Cancer With Bone Metastases
Hongmei Li, Tingting Xu, Qingchu Hua, Li Wang, Yue Chen
Abstract
ABSTRACT: Bone is the most common metastatic site in patients with prostate cancer. 177Lu-DOTA-ibandronic acid (177Lu-DOTA-IBA) is a new therapeutic radiopharmaceutical targeting bone metastasis. We report a case of refractory bone pain due to bone metastasis, who demonstrated an excellent therapy response after 3 cycles of 177Lu-DOTA-IBA therapy. In addition, the patient did not have any observable adverse reactions. 177Lu-DOTA-IBA may be a promising radiopharmaceutical for the treatment of bone metastasis.
Topics & Concepts
MedicineProstate cancerDOTABone metastasisRefractory (planetary science)MetastasisBone painBone imagingOncologyNuclear medicineCancerInternal medicineIn vivoBiotechnologyPhysicsBiologyAstrobiologyBone health and treatmentsRadiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and Research